DrugCentral 2021 supports drug discovery and repositioning

Author:

Avram Sorin1,Bologa Cristian G23,Holmes Jayme2,Bocci Giovanni2,Wilson Thomas B4,Nguyen Dac-Trung5ORCID,Curpan Ramona1,Halip Liliana1,Bora Alina1,Yang Jeremy J2,Knockel Jeffrey6,Sirimulla Suman7,Ursu Oleg8,Oprea Tudor I28910ORCID

Affiliation:

1. Department of Computational Chemistry, “Coriolan Dragulescu’’ Institute of Chemistry, 24 Mihai Viteazu Blvd, Timişoara, Timiş, 300223, România

2. Translational Informatics Division, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA

3. UNM Comprehensive Cancer Center, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA

4. College of Pharmacy, University of New Mexico Health Sciences Center, Albuquerque, NM 87131, USA

5. National Center for Advancing Translational Science, 9800 Medical Center Drive, Rockville, MD 20850, USA

6. Department of Computer Science, University of New Mexico, Albuquerque, NM 87131, USA

7. Department of Pharmaceutical Sciences, School of Pharmacy, The University of Texas at El Paso, TX 79902, USA

8. Computational and Structural Chemistry, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA

9. Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, 40530 Gothenburg, Sweden

10. Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark

Abstract

AbstractDrugCentral is a public resource (http://drugcentral.org) that serves the scientific community by providing up-to-date drug information, as described in previous papers. The current release includes 109 newly approved (October 2018 through March 2020) active pharmaceutical ingredients in the US, Europe, Japan and other countries; and two molecular entities (e.g. mefuparib) of interest for COVID19. New additions include a set of pharmacokinetic properties for ∼1000 drugs, and a sex-based separation of side effects, processed from FAERS (FDA Adverse Event Reporting System); as well as a drug repositioning prioritization scheme based on the market availability and intellectual property rights forFDA approved drugs. In the context of the COVID19 pandemic, we also incorporated REDIAL-2020, a machine learning platform that estimates anti-SARS-CoV-2 activities, as well as the ‘drugs in news’ feature offers a brief enumeration of the most interesting drugs at the present moment. The full database dump and data files are available for download from the DrugCentral web portal.

Funder

National Institutes of Health

National Cancer Institute

NIH NCATS Clinical and Translational Science Center for UNM

Intramural Research Program, Division of Preclinical Innovation, NIH NCATS

National Science Foundation

Publisher

Oxford University Press (OUP)

Subject

Genetics

Cited by 125 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3